Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

View All Documentation

Y0000598

Medroxyprogesterone acetate for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C24H34O4
Numer CAS:
71-58-9
Masa cząsteczkowa:
386.52
Beilstein:
2066112
Numer MDL:
MFCD00010483
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329831042
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

medroxyprogesterone

producent / nazwa handlowa

EDQM

mp

206-207 °C (lit.)

Zastosowanie

pharmaceutical (small molecule)

format

neat

ciąg SMILES

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

Klucz InChI

PSGAAPLEWMOORI-PEINSRQWSA-N

informacje o genach

human ... PGR(5241)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Medroxyprogesterone acetate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

produkt powiązany

Numer produktu
Opis
Cennik

1378001

Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard

1378012

Medroxyprogesterone acetate Related Compound A, United States Pharmacopeia (USP) Reference Standard

M0250000

Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard

Y0001484

Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

PHR1589

Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

1378023

Medroxyprogesterone acetate Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP221

Medroxyprogesterone acetate, British Pharmacopoeia (BP) Reference Standard

Piktogramy

Health hazard
GHS08

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

H351,H413

Zwroty wskazujące środki ostrożności

P202 - P273 - P280 - P308 + P313 - P405 - P501

Klasyfikacja zagrożeń

Aquatic Chronic 4 - Carc. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

Przepraszamy, ale COA dla tego produktu nie jest aktualnie dostępny online.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Léanie Kleynhans et al.
Infection and immunity, 81(4), 1234-1244 (2013-02-06)
The contraceptive depot medroxyprogesterone acetate (DMPA), with progestin as the single active compound, possesses selective glucocorticoid activity and can alter the expression of glucocorticoid receptor-regulated genes. We therefore propose that pharmacological doses of DMPA used for endocrine therapy could have
Lee L Lanza et al.
Obstetrics and gynecology, 121(3), 593-600 (2013-05-03)
Depot medroxyprogesterone acetate (DMPA) reversibly reduces bone mineral density. To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice
Robert A Wild et al.
Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)
Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control
Richard P H Huijbregts et al.
Endocrinology, 154(3), 1282-1295 (2013-01-29)
Recent observational studies indicate an association between the use of hormonal contraceptives and acquisition and transmission of HIV-1. The biological and immunological mechanisms underlying the observed association are unknown. Depot medroxyprogesterone acetate (DMPA) is a progestin-only injectable contraceptive that is
JoAnn E Manson et al.
JAMA, 310(13), 1353-1368 (2013-10-03)
Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej